Check-Cap (NASDAQ:MBAI) Research Coverage Started at Northland Securities

Northland Securities began coverage on shares of Check-Cap (NASDAQ:MBAI) in a report released on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $10.00 target price on the stock. Northland Securities also issued estimates for Check-Cap’s FY2026 earnings at ($0.02) EPS, FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.58 EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Check-Cap in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Check-Cap Stock Performance

MBAI opened at $3.54 on Monday. The firm has a market cap of $4.89 million, a P/E ratio of -0.25 and a beta of 0.67. Check-Cap has a 52-week low of $3.34 and a 52-week high of $27.44. The business’s fifty day moving average is $7.04 and its 200-day moving average is $9.36.

Check-Cap Company Profile

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.